About This Statistic
This statistic displays the top 5 global vaccine products based on their revenues worldwide in 2016, and a projection for 2022. Pfizer's pneumococcal vaccine, Prevnar 13, is expected to generate some 5.75 billion U.S. dollars in revenues by 2022. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Top vaccine products
Vaccines act as a preventive measure to improve immunity to certain diseases. Often, vaccines are created from a weakened or killed form of a microbe which allows the immune system to react and create a record of it, so that in the future, it can easily recognize these microorganisms. Vaccine use can easily help to prevent contraction of certain viruses such as influenza. However, some countries may not have easy access to vaccinations. In India, there were approximately 1.8 million deaths due to vaccine-preventable diseases as of 2013.
The global vaccination market generated 27.5 billion U.S. dollars in 2016 and is projected to total around 35 billion U.S. dollars in 2022. As of 2014, there were 18 new vaccines that were moving along the research and development pipeline for neglected diseases. Vaccines in the United States accumulated some of the world’s largest revenues, totaling 10.8 billion U.S. dollars in 2013. In comparison, Germany generated around three billion U.S. dollars at the vaccine market. Prevnar 13 and Gardasil are the top vaccines in the world, generating 6 billion and 2.5 billion U.S. dollars, respectively, in 2016. Prevnar 13 is marketed by Pfizer and Daewoong.